These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26798966)

  • 1. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
    Pant S; Jones SF; Kurkjian CD; Infante JR; Moore KN; Burris HA; McMeekin DS; Benhadji KA; Patel BKR; Frenzel MJ; Kursar JD; Zamek-Gliszczynski MJ; Yuen ESM; Chan EM; Bendell JC
    Eur J Cancer; 2016 Mar; 56():1-9. PubMed ID: 26798966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
    Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
    Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
    Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
    J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
    Krop I; Demuth T; Guthrie T; Wen PY; Mason WP; Chinnaiyan P; Butowski N; Groves MD; Kesari S; Freedman SJ; Blackman S; Watters J; Loboda A; Podtelezhnikov A; Lunceford J; Chen C; Giannotti M; Hing J; Beckman R; Lorusso P
    J Clin Oncol; 2012 Jul; 30(19):2307-13. PubMed ID: 22547604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.
    Aung KL; El-Khoueiry AB; Gelmon K; Tran B; Bajaj G; He B; Chen T; Zhu L; Poojary S; Basak S; Qi Z; Spreafico A; Fischer BS; Desai J
    Invest New Drugs; 2018 Dec; 36(6):1026-1036. PubMed ID: 29637471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
    Messersmith WA; Shapiro GI; Cleary JM; Jimeno A; Dasari A; Huang B; Shaik MN; Cesari R; Zheng X; Reynolds JM; English PA; McLachlan KR; Kern KA; LoRusso PM
    Clin Cancer Res; 2015 Jan; 21(1):60-7. PubMed ID: 25231399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
    Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
    Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Bahleda R; Grilley-Olson JE; Govindan R; Barlesi F; Greillier L; Perol M; Ray-Coquard I; Strumberg D; Schultheis B; Dy GK; Zalcman G; Weiss GJ; Walter AO; Kornacker M; Rajagopalan P; Henderson D; Nogai H; Ocker M; Soria JC
    Br J Cancer; 2017 Jun; 116(12):1505-1512. PubMed ID: 28463960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
    Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
    Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer.
    Feng Z; Xu W; Zhang C; Liu M; Wen H
    Oncotarget; 2017 Jan; 8(5):8215-8225. PubMed ID: 28030808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
    J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.